European Medicines Agency holds first meeting of expert group on the replacement, reduction and refinement of the use of animals
The European Medicines Agency has established an ad-hoc expert group on the application of the '3Rs' - replacement, reduction and refinement of animal testing - in the development of medicines.
The group, whose first meeting started today, will give advice and recommendations to the Agency's Committee for Medicinal Products for Human Use (CHMP) and Committee for Medicinal Products for Veterinary Use (CVMP) on the use of animals and the application of the 3Rs in the testing of human and veterinary medicines.
The Agency established the expert group in order to foster the implementation of the 3Rs agenda in the testing of medicines for regulatory purposes and to allow the Agency and its network of regulatory and scientific experts to contribute to developments in the 3Rs area. One of the group's first tasks will be to discuss the final wording of its mandate and work plan, before forwarding these documents to the CVMP and CHMP for approval.
The group is made up of experts from the CHMP and CVMP working parties, who will meet twice a year. The Agency will review the work of the group after around two years of operation.